Glaucoma | Medical XPRT
Articles & Whitepapers
-
Advances in siRNA Drug Research
siRNA, with a molecular weight of about 13 kDa, recruits the RNA-induced silencing complex (RISC) to mRNA through base pairing, thereby inhibiting protein translation. The mRNA is targeted for cleavage through the catalysis of the RISC protein Ago2, a member of the Argonaute family. In addition, other Ago proteins (Ago1, Ago3, and Ago4) catalyze endonuclease-mediated degradation of non-specific ...
-
Has the future of complement therapeutics arrived?
Silence Therapeutics, a pioneer in the development of novel small interfering RNA (siRNA) therapeutics, and Mallinckrodt plc, a global biopharmaceutical company, announced the submission of a ...
News
-
5 Ways OCT Technology Can Benefit Your Practice
The human eye is an amazing organ. With the fastest muscle in your body, it contains 107 million cells and can differentiate approximately 10 million colors. But when it comes to detecting severe conditions like glaucoma and macular degeneration, ...
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (`NSERC`) Alliance Grant Funding
iSTAR Medical appoints leading glaucoma specialist Prof. Kaweh Mansouri as Chief Medical Officer
MediPrint™ Ophthalmics Announces Acceptance and Presentation of Poster at the Upcoming GSLS in Las Vegas
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
Equipment & Solutions
-
Showcase
Ocular Hypertension Biotechnology
Ocular hypertension, is defined as having a raised eye pressure greater than 21 mmHg. Ocular hypertension is a proven major risk factor for developing glaucoma and eye drops are recommended to lower the pressure.